Qiagen and Abbott end HPV litigation with molecular Dx agreement
This article was originally published in Clinica
Executive Summary
Qiagen and Abbott have ended their legal tussle over patents relating to human papillomavirus (HPV) tests by signing a licensing agreement covering a range of in vitro diagnostics technology.